Aday kit

Aday Kit is a pre-packaged, dual-hormonal medical regimen combining two distinct active pharmaceutical ingredients: mifepristone and misoprostol. Together, these medications act sequentially to terminate an early intrauterine pregnancy (typically up to 63 to 70 days / 9 to 10 weeks of gestation) or manage incomplete abortions and early pregnancy loss:

• Mifepristone (200 mg – 1 tablet): A synthetic antiprogestational agent that blocks progesterone receptors, blocking the hormone necessary to sustain pregnancy. This leads to the detachment of the blastocyst and softening/dilation of the cervix.

• Misoprostol (200 mcg – 4 tablets): A synthetic prostaglandin $E_1$ ($PGE_1$) analog that induces myometrial contractions and cervical ripening, resulting in the expulsion of the uterine contents.

Primary Medical Indications

Aday Kit is indicated for use under direct medical supervision and clinical protocols for:

• Medical Termination of Early Intrauterine Pregnancy: Induction of abortion in early pregnancy (up to 63–70 days gestation from the first day of the last menstrual period).

• Management of Early Pregnancy Loss / Incomplete Miscarriage: Medical management of an embryonic or fetal demise or incomplete spontaneous abortion.

• Cervical Ripening: Softening and priming of the cervix prior to surgical uterine evacuation procedures.

Key Product Specifications & Dosing Regimen

Critical Safety Guidelines & Precautions

• Ultrasound & Gestational Confirmation: Before administration, ectopic pregnancy must be ruled out via clinical evaluation or pelvic ultrasound. Aday Kit is ineffective against ectopic pregnancies and can obscure rupture symptoms.

• Contraindications: Strictly contraindicated in patients with confirmed or suspected ectopic pregnancy, intrauterine device (IUD) in place (must be removed prior), chronic adrenal failure, severe unmanaged asthma, hemorrhagic disorders, or concurrent anticoagulant therapy.

• Expected Side Effects vs. Medical Emergencies: Cramping and vaginal bleeding are expected outcomes of the treatment. Clinical evaluation is urgently required if a patient experiences:

  • Heavy bleeding (soaking through 2 or more thick sanitary pads per hour for 2 consecutive hours).

  • Severe abdominal pain unresponsive to analgesics.

  • Fever of $38^\circ\text{C}$ ($100.4^\circ\text{F}$) or higher lasting more than 4 hours, or starting more than 24 hours after misoprostol administration.

• Rhesus Immunization: Rh negative patients require administration of Rho(D) immune globulin to prevent Rh sensitization.

• Follow-Up Assessment: A follow-up clinical examination or ultrasound is essential 7 to 14 days post-treatment to confirm complete clearance of uterine contents and rule out incomplete abortion or infection.